| abstract |
Disclosed is the use of compounds of the formula (I), wherein; X is O or S; j is 0-1; p is 0-3; q is 0-2; r is 0-3; Z is -OH; -Oalkyi; -NR3R4, where R3 and R4 are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, and heterocyclic, or R3 and R4 may combine with N to form a ring where the ring atoms are selected from the group consisting of CH2 N, O and S or formula (II); wherein Y is independently CH2, O, N or S, Q is C or N; n is independently 0-4; and m is 0-3 or a salt thereof, for the manufacture of a medicament for the treatment of acute myeloid leukemia in a patient, wherein the patient is FLT-3-ITD positive. |